The progression of myopic maculopathy may affect the long-term VA outcome of myopic CNV treatment. We evaluated the long-term progression of myopic maculopathy and functional outcome after treatment of myopic choroidal neovascularization (CNV) with photodynamic therapy (PDT) and/or intravitrealranibizumab (IVR). This was a retrospective study with a cross-sectional evaluation, including fifty-four eyes with a mean follow-up of 80.6 ± 28.0 months. Eyes were assigned to 4 groups (photodynamic therapy (PDT), IntravitreousRanibizumab (IVR), PDT + IVR, dry myopic maculopathy) and evaluated with best-corrected visual acuity, color fundus photography and spectral-domain optical coherence tomography.

The prevalence of diffuse, patchy and macular atrophy increased during the follow-up, in contrast with tessellated fundus, lacquer cracks and active CNV. Progression of macular atrophy was significant in the 3 treatment groups (p < 0.05) and predictive of visual acuity. It depended on age, degree of myopia and presence of staphyloma, but not on the type of treatment. The long-term functional outcome of eyes with myopic CNV was more likely to be dependent on the progression of macular atrophy, than on the type of treatment.